From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Abexinostat (INN,[1] formerly PCI-24781) is an experimental drug candidate for cancer treatment.[2] It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma.[3] Pre-clinical study suggests the potential for treatment of different types of cancer as well.[4][5][6][7]

Abexinostat exerts its effect as a pan-histone deacetylase inhibitor[8][9] and inhibits RAD51, which is involved in repairing DNA double strand breaks.[10]


  1. WHO Drug Information, Vol. 25, No. 2, 2011
  2. Abexinostat, NCI Cancer Dictionary
  3. Abexinostat HCl (PCI-24781), PanHDAC-inhibitor Archived 2013-10-27 at the Wayback Machine, Pharmacyclics

Latest research - Abexinostat

Clinical trials

Abexinostat is part of WikiMD's free ^articles!

^Abexinostat (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Overweight?. W8MD's physician weight loss & sleep medicine program can HELP. Philadelphia lose weight. NYC lose weight Tele weight loss available